The IL-6/gp130/STAT3 signaling axis: Recent advances towards specific inhibition

Current Opinion in Immunology

Volumn 34, Issue , 2015, Pages 75-82

  Garbers, Christoph ^a   Aparicio Siegmund, Samadhi ^a   Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; GLYCOPROTEIN GP 130; HOMODIMER; HYBRID PROTEIN; INTERLEUKIN 11; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; NEUTRALIZING ANTIBODY; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; INFLAMMATORY DISEASE; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INFLAMMATION; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84924560120     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.02.008     Document Type: Review

References (61)

1. Chang Q., Daly L., Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014, 26:48-53.
2. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52:199-219.
3. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014, 6:a016295.
4. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014, 70:11-20.
5. Scheller J., Garbers C., Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014, 26:2-12.
6. Babon J.J., Varghese L.N., Nicola N.A. Inhibition of IL-6 family cytokines by SOCS3. Semin Immunol 2014, 26:113-119.
7. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., Jones S.A., Rose-John S., Scheller J. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
8. Barkhausen T., Tschernig T., Rosenstiel P., van Griensven M., Vonberg R.P., Dorsch M., Mueller-Heine A., Chalaris A., Scheller J., Rose-John S., et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 2011, 39:1407-1413.
9. Luig M., Kluger M.A., Goerke B., Meyer M., Nosko A., Yan I., Scheller J., Mittrucker H.W., Rose-John S., Stahl R.A., et al. Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN. J Am Soc Nephrol 2015, (in press).
10. Mauer J., Denson J.L., Bruning J.C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015, 36:92-101.
11. Chalaris A., Garbers C., Rabe B., Rose-John S., Scheller J. The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011, 90:484-494.
12. Böttcher J.P., Schanz O., Garbers C., Zaremba A., Hegenbarth S., Kurts C., Beyer M., Schultze J.L., Kastenmüller W., Rose-John S., et al. IL-6 trans-signaling-dependent rapid development of cytotoxic CD8(+) T cell function. Cell Rep 2014, 8:1318-1327.
13. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Klöppel G., Yoshimura A., Reindl W., Sipos B., Akira S., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
14. Sommer J., Garbers C., Wolf J., Trad A., Moll J.M., Sack M., Fischer R., Grötzinger J., Waetzig G.H., Floss D.M., et al. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10. J Biol Chem 2014, 289:22140-22150.
15. Zhang H., Neuhöfer P., Song L., Rabe B., Lesina M., Kurkowski M.U., Treiber M., Wartmann T., Regnér S., Thorlacius H., et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest 2013, 123:1019-1031.
16. Schuett H., Oestreich R., Waetzig G.H., Annema W., Luchtefeld M., Hillmer A., Bavendiek U., von Felden J., Divchev D., Kempf T., et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012, 32:281-290.
17. Wunderlich C.M., Delić D., Behnke K., Meryk A., Ströhle P., Chaurasia B., Al-Quraishy S., Wunderlich F., Brüning J.C., Wunderlich F.T. Cutting edge: inhibition of IL-6 trans-signaling protects from malaria-induced lethality in mice. J Immunol 2012, 188:4141-4144.
18. Campbell I.L., Erta M., Lim S.L., Frausto R., May U., Rose-John S., Scheller J., Hidalgo J. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 2014, 34:2503-2513.
19. Hoge J., Yan I., Jänner N., Schumacher V., Chalaris A., Steinmetz O.M., Engel D.R., Scheller J., Rose-John S., Mittrücker H.-W.W. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 2013, 190:703-711.
20. Sodenkamp J., Waetzig G.H., Scheller J., Seegert D., Grötzinger J., Rose-John S., Ehlers S., Hölscher C. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 2012, 217:996-1004.
21. Harker J.A., Lewis G.M., Mack L., Zuniga E.I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 2011, 334:825-829.
22. Harker J.A., Dolgoter A., Zuniga E.I. Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4(+) T cell responses and viral control during chronic infection. Immunity 2013, 39:548-559.
23. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8:1237-1247.
24. Calabrese L.H., Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014, 10:720-727.
25. Nowell M.A., Richards P.J., Horiuchi S., Yamamoto N., Rose-John S., Topley N., Williams A.S., Jones S.A. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003, 171:3202-3209.
26. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989, 169:333-338.
27. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005, 23:1-21.
28. Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001, 268:160-167.
29. Garbers C., Monhasery N., Aparicio-Siegmund S., Lokau J., Baran P., Nowell M.A., Jones S.A., Rose-John S., Scheller J. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim Biophys Acta 2014, 1842:1485-1494.
30. Ferreira R.C., Freitag D.F., Cutler A.J., Howson J.M., Rainbow D.B., Smyth D.J., Kaptoge S., Clarke P., Boreham C., Coulson R.M., et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet 2013, 9:e1003444.
31. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205-1213.
32. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012, 379:1214-1224.
33. Garbers C., Hermanns H., Schaper F., Müller-Newen G., Grötzinger J., Rose-John S., Scheller J. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012, 23:85-182.
34. Dechow T., Steidle S., Götze K.S., Rudelius M., Behnke K., Pechloff K., Kratzat S., Bullinger L., Fend F., Soberon V., et al. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 2014, 124:5263-5274.
35. Crabé S., Guay-Giroux A., Tormo A.J., Duluc D., Lissilaa R., Guilhot F., Mavoungou-Bigouagou U., Lefouili F., Cognet I., Ferlin W.G., et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J Immunol 2009, 183:7692-7702.
36. Tormo A., Meliani Y., Beaupré L., Sharma M., Fritz J., Elson G., Crabé S., Gauchat J.-F. The composite cytokine p28/cytokine-like factor 1 sustains B cell proliferation and promotes plasma cell differentiation. J Immunol 2013, 191:1657-1665.
37. Garbers C., Spudy B., Aparicio-Siegmund S., Waetzig G.H., Sommer J., Hölscher C., Rose-John S., Grötzinger J., Lorenzen I., Scheller J. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem 2013, 288:4346-4354.
38. Stumhofer J.S., Tait E.D., Quinn W.J., Hosken N., Spudy B., Goenka R., Fielding C.A., O'Hara A.C., Chen Y., Jones M.L., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol 2010, 11:1119-1126.
39. Dibra D., Cutrera J., Xia X., Kallakury B., Mishra L., Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology (Baltim, MD) 2012, 55:1204-1214.
40. Wang R.-X.X., Yu C.-R.R., Mahdi R.M., Egwuagu C.E. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem 2012, 287:36012-36021.
41. Collison L., Workman C., Kuo T., Boyd K., Wang Y., Vignali K., Cross R., Sehy D., Blumberg R., Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
42. Collison L., Delgoffe G., Guy C., Vignali K., Chaturvedi V., Fairweather D., Satoskar A., Garcia K., Hunter C., Drake C., et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012, 13:290-299.
43. Wang R.-X.X., Yu C.-R.R., Dambuza I.M., Mahdi R.M., Dolinska M., Sergeey Y.V., Wingfield P.T., Kim S.-H.H., Egwuagu C.E. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014, 20:633-641.
44. Chow D., He X., Snow A.L., Rose-John S., Garcia K.C. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001, 291:2150-2155.
45. Aparicio-Siegmund S., Moll J.M., Lokau J., Grusdat M., Schröder J., Plöhn S., Rose-John S., Grötzinger J., Lang P.A., Scheller J., et al. Recombinant p35 from bacteria can form interleukin (IL-)12, but not IL-35. PLOS ONE 2014, 9:e107990.
46. Ferraccioli G., Bracci-Laudiero L., Alivernini S., Gremese E., Tolusso B., De Benedetti F. Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010, 16:552-557.
47. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 10:578-582.
48. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu Rev Immunol 1998, 16:293-322.
49. Schuster B., Kovaleva M., Sun Y., Regenhard P., Matthews V., Grotzinger J., Rose-John S., Kallen K.J. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem 2003, 278:9528-9535.
50. Aparicio-Siegmund S., Sommer J., Monhasery N., Schwanbeck R., Keil E., Finkenstädt D., Pfeffer K., Rose-John S., Scheller J., Garbers C. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014, 5:2131-2148.
51. Waetzig G.H., Rose-John S. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 2012, 16:225-236.
52. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011, 121:3375-3383.
53. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888.
54. Scheller J., Schuster B., Hölscher C., Yoshimoto T., Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun 2005, 326:724-728.
55. Pflanz S., Tacken I., Grotzinger J., Jacques Y., Minvielle S., Dahmen H., Heinrich P.C., Muller-Newen G. A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett 1999, 450:117-122.
56. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
57. Spehlmann M.E., Manthey C.F., Dann S.M., Hanson E., Sandhu S.S., Liu L.Y., Abdelmalak F.K., Diamanti M.A., Retzlaff K., Scheller J., et al. Trp53 deficiency protects against acute intestinal inflammation. J Immunol 2013, 191:837-847.
58. Atreya R., Mudter J., Finotto S., Müllberg J., Jostock T., Wirtz S., Schütz M., Bartsch B., Holtmann M., Becker C., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588.
59. Mitsuyama K., Matsumoto S., Rose-John S., Suzuki A., Hara T., Tomiyasu N., Handa K., Tsuruta O., Funabashi H., Scheller J., et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006, 55:1263-1269.
60. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
61. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., Scheller J., Rose-John S., Kado S., Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010, 184:1543-1551.